Online inquiry

IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2787MR)

This product GTTS-WQ2787MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IL1RL1 gene. The antibody can be applied in Allergic asthma research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001282408.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 9173
UniProt ID Q01638
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ2787MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ926MR IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-321
GTTS-WQ10173MR IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LC1004-002
GTTS-WQ10197MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, LDP-02(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LDP-02
GTTS-WQ10146MR IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LBR-101
GTTS-WQ14677MR IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SCT-400
GTTS-WQ4556MR IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-936564
GTTS-WQ2242MR IVTScrip™ mRNA-Anti-VWF, aVWF81(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA aVWF81
GTTS-WQ15054MR IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA SRF-231
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW